image credit: Pxhere

Keytruda gains eighth FDA approval this year

December 7, 2021


In its eighth US approval of the year, the Food and Drug Administration (FDA) has given the green light to use Keytruda as an adjuvant treatment for adults and children aged 12 years and over who have stage 2b and 2c melanoma and have received surgery to resect the tumour.

This indication is important, says Dr Jason Luke from the Cancer Immunotherapeutics Center at UPMC Hillman Cancer Center, because the standard of care is currently observation despite the fact that the risk of recurrence is nearly the same as it is for patients with later-stage disease, where treatment is recommended.

Read More on PMLiVE